Company: OSRH
Filing Date: 2025-01-24
Form Type: S-4/A
Source: 0001213900-25-006139
Chunk: 281

Company: OSR Holdings, Inc.
Filing Date: 2025-01-24
Form: S-4/A
Chunk 281
---
 the degree that it does not affect the BLAC M&A Committee’s existing opinion and conclusion regarding the Business Combination, including the value of OSR Holdings. The BLAC M&A Committee reached this conclusion because it believes that RMC’s active relationships with the large hospital and clinic clients nationwide in Korea will allow RMC to generate operating leverage on its distribution network by substituting new medical device and supply products which were deemed to be reasonably available following the closing of the Business Combination. While sales in 2025 are likely to decline due to the Penumbra contract termination, RMC has the capability of adding new supplier relationships to expand RMC’s product portfolio for the hospitals and clinics who are actual customers and with whom RMC retains relationships. For additional information regarding the termination of the Penumbra agreement, see the section entitled “OSR Holdings Management’s Discussion and Analysis of Financial Condition and Results of Operations — Impacts of COVID -19 and Market Conditions on Our Business. ” The BLAC M&A Committee’s Reasons for the Approval of the Business Combination The BLAC M&A Committee, in evaluating the Business Combination, consulted with BLAC’s management and legal advisors. In reaching its unanimous decision to approve the Business Combination Agreement and the transactions contemplated by the Business Combination Agreement, the BLAC M&A Committee considered various factors in connection with its evaluation of the Business Combination. Due to the complexity of those factors, the BLAC M&A Committee did not consider it practicable to, nor did it attempt to, quantify or otherwise assign relative weights to the specific factors it took into account in reaching its decision. The BLAC M&A Committee viewed its decision as being based on all of the information available and the factors presented to and considered by it. In addition, individual members of the BLAC M&A Committee may have given different weight to different factors. This explanation of the reasons for the BLAC M&A Committee’s approval of the Business Combination, and all other information presented in this section, is forward -lookingin nature and, therefore, should be read in light of the factors discussed in the section entitled. “ Cautionary Note Regarding Forward -Looking Statements.” In considering approving the Business Combination, the BLAC M&A Committee and the full BLAC Board conditioned the approval on obtaining a fairness opinion from a financial advisory firm prior to the closing of the Business Combination. In addition, the officers and directors of BLAC have substantial experience in evaluating the operating and financial merits of companies from a wide range of industries including healthcare and concluded that their experience and background,